Y90 Radioembolization

Episode #265

In this crossover episode between BackTable VI and BackTable Innovation, Dr. Chris Beck interviews Dr. Riad Salem (Chief of Interventional Radiology at Northwestern University) and Peter Pattison (President of Interventional Oncology at Boston Scientific) about how TheraSpheres for Y90 radioembolization became a mainstay in the IR toolkit for HCC and where the technology is heading next.

Episode #245

In this episode, host Dr. Ally Baheti interviews Dr. Jayson Brower about building a Y90 service line in his outpatient based lab (OBL).

Episode #137

Dr. Rakesh Ahuja walks us through the Pathway to Becoming a Y-90 Authorized user as a Resident, as well as the standard post-training pathway.

Episode #92

Interventional Radiologist Justin Lee tells us about his approach to treatment of Hepatocellular Carcinoma (HCC), including how this has changed over his years in private practice. This is part two of a two part series.

Episode #91

Interventional Radiologist Justin Lee tells us how he started from scratch in growing a robust Interventional Oncology program in private practice, including pitfalls to avoid. This is part one of a two part series.

Episode #78

Interventional Radiologists Dr. Sam Mouli from Northwestern University and Dr. Sandeep Bagla discuss new research examining Y-90 Radioembolization as a novel therapeutic option for treating prostate cancer.

Episode #76

Interventional Radiologist Terence Gade from Penn Medicine, University of Pennsylvania Health System tells us about emerging research and therapies targeting the tumor microenvironment in Hepatocellular carcinoma (HCC).

Episode #67

Interventional Radiologist Dr. Alex Kim and Dr. Christopher Beck discuss the utility of different locoregional liver therapies in bridging HCC patients to transplant.

Episode #64

Transplant Surgeon Dr. Jennifer Berumen and Interventional Radiologist Dr. Isabel Newton discuss the treatment of HCC and the importance of multi-specialty collaboration in bridging these patients to successful liver transplantation. Special discussion was given around this HCC consortium article in Annals of Surgery: https://pubmed.ncbi.nlm.nih.gov/30870180/

Episode #32

Interventional Radiologist Dr. Julie Zaetta and Oncologist Dr. Natalie Stanton discuss the essentials of building a successful Interventional Oncology program, including the importance of a multidisciplinary approach.

Episode #20

Our 20th BackTable podcast episode featuring special guests Dr. Justin Lee of Florida Interventional Specialists, and Dr. Terence Gade of Hospital of University of Pennsylvania. They discuss experiences and utility of pressure-directed, antireflux infusion for TACE treatments.

Episode #16

Dr. Charles Nutting FSIR of RIA Endovascular and Dr. Nainesh Parikh of Moffitt Cancer Center. They discuss pressure-directed, antireflux infusion for Y90 Radioembolization, including the SureFire Infusion system.

A pressure directed device may help increase control of Y90 radioembolization delivery to the tumor in hepatocellular carcinoma (HCC). Having performed around 200 pressure directed procedures, Dr. Nutting describes his use of Surefire’s guide catheter and microcatheters when working with the Surefire Infusion System.

When treating HCC with Y90 radioembolization, a hypovascular tumor with low visibility on angiogram can indicate that a pressure directed device may help to deliver more of the intended dose to the tumor. Studies have shown that pressure directed devices increase tumor uptake and decrease non-target embolization.

The goal of Y90 radioembolization is to deliver the full dose of therapeutic to the tumor. Pressure directed therapy intermittently stops arterial flow and pushes therapeutic into the tumor using pressure that builds up during infusion, overcoming some of the technical limitations of end-hole catheters.

​

​

The Child-Pugh Score calculator can be used to quickly assess the severity of cirrhosis, life expectancy, and risk of perioperative abdominal surgery mortality in patients with liver disease.

Model for End-Stage Liver Disease. Stratifies severity of end-stage liver disease, for transplant planning.